kallyope

Kallyope

Company: Kallyope Inc. Headquarters: New York, New York, USA Founded: 2015 Funding: $272 million (total) Ownership: Private

Overview

Kallyope

Company: Kallyope Inc. Headquarters: New York, New York, USA Founded: 2015 Funding: $272 million (total) Ownership: Private

Overview

Kallyope is a biotechnology company focused on understanding the [gut-brain axis](/entities/gut-brain-axis) and developing therapeutics for neurological and metabolic diseases. The company was founded by leading scientists in the field of gut-brain communication and has built a proprietary platform to map the complex signaling between the gastrointestinal tract and the central nervous system["@kallyope"].

The gut-brain axis represents one of the most exciting frontiers in neuroscience, with emerging evidence linking gut health to conditions ranging from [Parkinson's disease and [Alzheimer's disease to depression and anxiety. Kallyope's mission is to translate this scientific understanding into novel treatments for patients with serious neurological disorders.

Science and Technology

Gut-Brain Axis

The gut-brain axis is a bidirectional communication network connecting the gastrointestinal tract with the central nervous system:

Communication Pathways:

Kallyope's Platform

Kallyope has built an integrated platform combining:

Technologies:

• Single-cell sequencing of gut cells
• Computational biology and machine learning
• Genetic tools for circuit mapping
• Human organoid models
• Clinical translation capabilities

• Cell atlases of the gut
• Gut-brain circuit maps
• [Microbiome](/entities/microbiome) sequencing databases
• Clinical patient cohorts

Therapeutic Programs

Parkinson's disease Disease

Kallyope has a significant focus on [Parkinson's disease, driven by the growing understanding of gut involvement in PD pathogenesis:

| Program | Target | Mechanism | Stage |
|---------|--------|-----------|-------|
| K-141 | [GBA](/entities/gba) | Gene therapy for GBA-associated PD | Preclinical |
| K-142 | [LRRK2](/entities/lrrk2) | Small molecule LRRK2 modulator | Discovery |
| K-149 | [Alpha-synuclein](/proteins/alpha-synuclein) | Microbiome-targeted intervention | Discovery |

Gut Hypothesis in Parkinson's disease

Kallyope's approach is grounded in the emerging hypothesis that [Parkinson's disease](/diseases/parkinsons-disease) may start in the gut:

• Alpha-synuclein aggregation: May initiate in enteric [neurons](/entities/neurons)
• Vagus nerve spread: Pathological proteins may travel to the brain via the vagus nerve
• Microbiome changes: PD patients show distinct gut microbiome alterations
• Inflammation: Gut-derived inflammation may drive CNS pathology

Alzheimer's disease Disease

| Program | Target | Mechanism | Stage |
|---------|--------|-----------|-------|
| K-201 | APOE4 | Targeted intervention for APOE4 carriers | Discovery |
| K-205 | Microbiome | Microbial metabolite modulation | Preclinical |

Additional Programs

Kallyope is also active in:

• Metabolic diseases: Obesity, diabetes
• Mood disorders: Depression, anxiety
• Autism spectrum disorders

Business Model

Funding History

| Year | Round | Amount | Lead Investors |
|------|-------|--------|----------------|
| 2022 | Series C | $118M | The Column Group, Arch Venture |
| 2020 | Series B | $102M | Casdin Capital, Logos Capital |
| 2018 | Series A | $44M | Polaris Partners, The Column Group |
| 2016 | Seed | $8M | Various angels |

Collaborations

Kallyope has established collaborations with:

• Academic partners: Leading gut-brain researchers worldwide
• Pharma companies: Strategic partnerships for specific programs
• Patient foundations: Michael J. Fox Foundation, [Alzheimer's disease](/diseases/alzheimers-disease) Association

Leadership and Science

Scientific Founders

Kallyope was founded by renowned gut-brain scientists:

• Thomas G. Gasser, MD, PhD: Scientific Co-founder (Stanford)
• Michael S. Krouse, PhD: Scientific Co-founder (Stanford)
• John F. Cryan, PhD: Scientific Advisor (University College Cork)

Leadership Team

• Mark B. Gerstein, PhD: Chief Executive Officer
• Richard A. Muller, PhD: Chief Scientific Officer

Competitive Landscape

Kallyope operates in the emerging gut-brain axis therapeutics space:

Competitors:

• Vedanta Biosciences
• Finch Therapeutics
• Axial Therapeutics
• Yumanity (acquired by Pfizer)
• Caribou Biosciences

• Proprietary platform with unique biological insights
• Strong intellectual property position
• Experienced team with deep domain expertise
• Multiple shots on goal across diseases

Pipeline Summary

| Program | Indication | Stage | Modalities |
|---------|------------|-------|------------|
| K-141 | Parkinson's disease (GBA) | Preclinical | Gene therapy |
| K-142 | Parkinson's disease (LRRK2) | Discovery | Small molecule |
| K-149 | Parkinson's disease | Discovery | Microbiome |
| K-201 | Alzheimer's disease (APOE4) | Discovery | Biologic |
| K-205 | Alzheimer's disease | Preclinical | Microbiome |
| K-301 | Obesity | Phase 1 | Small molecule |

External Links

• [Kallyope Website](https://www.kallyope.com)
• [Kallyope Pipeline](https://www.kallyope.com/pipeline)

References